Pancreatic Cancer Clinical Trial
Official title:
Evaluation of the Diagnostic Value of TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer
Aim of the prospective study is a better differentiation of benign and malignant lesions in the pancreas in patients with suspected pancreatic cancer using images 30 and 90 min p.i. (post injectionen) and a diagnostic CT (computed tomography) scan of the abdomen within the Time of Flight (TOF)-18F-FDG-PET/CT and thus an improvement of the quality of PET/CT findings.
In the course of this the procedure follows the necessary steps of routine treatment:
1. Assignment of the patient with a suspect of pancreatic cancer.
2. Performing time of flight (TOF)-18F-FDG-PET/CT with images 30 min and 90 min p.i.
3. Performing a diagnostic CT of the abdomen with parenteral contrast medium and pancreatic
protocol (in case of normal creatinine, GFR, and TSH levels) as well as oral contrast
medium (in accordance with the ESUR-guidelines) as part of the PET/CT examination.
4. Routine performance of the operation /fine needle puncture/biopsy
5. Routine histopathological evaluation of the surgical specimen/biopsy
For this study, a diagnostic CT of the abdomen with contrast medium (intravenous as well as
oral) and with pancreatic protocol and without parenteral contrast medium in case of elevated
creatinine or decreased TSH (thyroid-stimulating hormone) or GFR (glomerular filtration rate)
levels is performed additionally within the routinely performed PET/CT for better
differentiation of the target organ from adjacent structures. Furthermore, early (30 min
p.i.) and delayed (90 min p.i.) images and a TOF-reconstruction following the PET/CT
examination (without patient contact) should be performed for better differentiation between
inflammatory and malignant lesions of the pancreas. The regional tracer-uptake should now be
measured quantitatively by SUV (Standard Uptake Value) in the TOF-PET/CT images over the
FDG-accumulating lesions in the pancreas at those two times. In case of an increased
FDG-uptake in the early images, the lesion will be assessed as benign/inflammatory and with
an increase of the FDG-uptake in the delayed images as malignant. No FDG-uptake in the early
as well as in the delayed images will be classified as benign. As a reference standard, the
histopathological diagnosis is used. Subsequently, a cut-off value of the SUV should be
determined by ROC-analysis.
According to current scientific evidence regarding the characterization of pancreatic masses
by means of "Time of Flight"(TOF)-technique, there are no studies in the literature.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
| Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
| Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
| Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|